

Design and Synthesis of Manganese-ligand Based Magnetic Resonance Imaging Contrast Agents


Changqiang Wu¹, Hongying Su¹, Tianxing Miao¹, Chunchao Xia², Qiyong Gong², Bin Song², Jiang Zhu³, Hua Ai^{1,2*}.

¹National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China

²Department of Radiology, West China Hospital, Sichuan University, Chengdu, China

³North Sichuan Medical College, Nanchong, China

Introduction: A contrast agent (CA) used in magnetic resonance imaging (MRI) clinical diagnosis can enhance the image quality. Obtain highly efficient and low mammalian toxicity contrast agent is the ultimate target in research. Optimization of molecular structure of CA can increase relaxivity and stability. We designed two new manganese complexes (MnL₁ and MnL₂), which are potential candidates as MRI contrast agents. The molecular structure of manganese complexes are as following.



Methods:

Pyridine-2, 6-dicarboxylic acid (99%, aladdin) and L-Proline (AstaTech) were used, (S)-2-(methoxycarbonyl) pyrrolidinium chloride obtained by esterifying L-Proline in methanol.

Synthesis of ligand1 (L₁):

Pyridine-2, 6-dicarboxylic acid (0.02mol) and thionyl chloride (50ml) were mixed in an ice bath. 0.4ml DMF was added in. Then, the solution was refluxed for 2 h. The excess thionyl chloride was evaporated. The residue was dissolved in 50ml chloroform. (S)-2-(methoxycarbonyl) pyrrolidinium chloride (0.04mol) and triethylamine (0.2mol) were dissolved in 100ml chloroform. The two solutions were mixed and stirred for 8h at room temperature. The solution was washed with water, product was obtained by recrystallization. The product was hydrolyzed in alkaline condition to obtain corresponding diacid (L₁).

Synthesis of ligand2 (L₂):

2, 6-bis(chloromethyl) pyridine was synthesized from pyridine-2, 6-dicarboxylic acid through three steps (Esterification in ethanol, reduction by sodium borohydride^[1], chlorination in thionyl chloride^[2]). 2, 6-bis(chloromethyl) pyridine (8 mmol), (S)-2-(methoxycarbonyl) pyrrolidinium chloride (16mmol) and K₂CO₃ (80 mmol) were mixed in 30ml acetonitrile, and stirred for 1h. Then, the solution was heated to reflux for 20 h. Filtered K₂CO₃ from solution, acetonitrile was evaporated off. The product was purified by silica gel column chromatography. The product was hydrolyzed in alkaline condition to obtain corresponding diacid (L₂).

Synthesis of manganese complexes (MnL₁/MnL₂):

1mmol Diacid (L₁ or L₂) was dissolved in 10ml water, 4mmol NaOH was added in and the mixture was degas under N₂. Then, 2 mmol MnCl₂ • 4H₂O was added in and stirred 12 h in room temperature. The water was removed by rotary evaporation and the resulting solid was suspended in 10 ml chloroform. The insoluble salts were removed by filtration and the filtrate was evaporated.

T₁ relaxivity studies:

T₁ relaxivities were measured at 1.5 T on a clinical MR scanner (Siemens Sonata) at room temperature^[3]. The T₁-weighted images were acquired with a conventional spin-echo acquisition (TE= 5.3 ms) with TR values ranging from 20 to 1000ms. Relaxivity values of r₁ were calculated through the curve fitting of 1/T₁ relaxation time (s⁻¹) from the versus concentration for 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45 and 0.5 mM Mn samples. All solutions were assayed for manganese concentration by atomic absorption spectroscopy (AAS).

Results:

The manganese complexes MnL₁ and MnL₂ were synthesized, and characterized by ESI-MS. The T₁ relaxivities of two manganese complexes, MnCl₂ and a commercial contrast agent (Gd-DTPA, magnevist) were measured, indicated in Figure 1.




Figure 1. T₁ weighted spin-echo MR phantom images of MnL₁, MnL₂, MnCl₂ and magnevist in water at equal molar concentration (0.4mM) of each contrast agent.

Images were acquired at 1.5 T at room temperature (TR/TE=90/5.3ms)

The r₁ values are listed in table 1. Relaxivity of manganese complexes are all better than magnevist, and MnL₁ has a highest r₁ value (6.4 mM⁻¹S⁻¹). The results are expectant. The MnL₁ complex has higher rigidity in molecular conformation, which may have some effects on T₁ relaxivity.

Table 1. Relaxivities of MRI Contrast Agents at 1.5T, room temperature

| Contrast Agents | r ₁ (mM ⁻¹ S ⁻¹) |
|-------------------|--|
| MnL ₁ | 6.4 |
| MnL ₂ | 3.4 |
| MnCl ₂ | 6.0 |
| Magnevist | 3.0 |

Conclusions:

We successfully designed and synthesized two new manganese contrast agents, which have better contrast over traditional commercial contrast agent. Biocompatibility and in vivo imaging tests are undergoing to examine their potentials as effective MRI probes.

References:

1. Chifuku K. Mol. Cryst. Liq. Cryst. 2007;470:369–381.
2. Engelhardt U. Polyhedron. 1995;14:2361-2369.
3. Lu J. Biomaterials. 2009;30:2919-2918.